Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:

NCT ID: NCT02892383 Active, not recruiting - Multiple Myeloma Clinical Trials

Quality of Life the Danish Multiple Myeloma Patients

QoL-MM
Start date: February 27, 2017
Phase:
Study type: Observational

The aim of the project is to improve quality of life for multiple myeloma patients in the future.

NCT ID: NCT02891811 Completed - Multiple Myeloma Clinical Trials

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Start date: March 10, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized, 2-arm phase II, multi-center study to evaluate the overall response rate in newly diagnosed, transplant ineligible patients receiving 9 cycles induction therapy with either KTd or KRd followed by randomization to either carfilzomib maintenance treatment for 12 months or to observation only. Maintenance is given for 12 cycles or progression of disease, whatever occurs first.

NCT ID: NCT02886065 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Start date: March 7, 2017
Phase: Phase 1
Study type: Interventional

This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: - Lenalidomide - Citarinostat (CC-96241) - PVX-410

NCT ID: NCT02884102 Active, not recruiting - Multiple Myeloma Clinical Trials

MMRF Molecular Profiling Protocol

Start date: June 2015
Phase:
Study type: Observational

This protocol is now being used as screening for the MyDRUG study

NCT ID: NCT02880228 Completed - Plasma Cell Myeloma Clinical Trials

Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

Start date: September 16, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are eligible for stem cell transplant. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab, lenalidomide, and dexamethasone may work better in treating patients with multiple myeloma.

NCT ID: NCT02874742 Completed - Multiple Myeloma Clinical Trials

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Start date: August 29, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the International Myeloma Working Group (IMWG) criteria, by the time of completion of post autologous stem cell transplantation (ASCT) consolidation treatment, compared with RVd alone.

NCT ID: NCT02869555 Recruiting - Multiple Myeloma Clinical Trials

Institut Paoli Calmettes Multiple Myeloma Database

Start date: January 2010
Phase: N/A
Study type: Observational [Patient Registry]

Database of Institut Paoli-Calmettes patients diagnosed with multiple myeloma

NCT ID: NCT02863991 Active, not recruiting - Multiple Myeloma Clinical Trials

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Start date: January 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

ONC201 is an orally bioavailable first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. This is a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone to patients with relapsed/refractory multiple myeloma. Funding Source - FDA OOPD

NCT ID: NCT02861287 Completed - Multiple Myeloma Clinical Trials

Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma

PLERIXAFOR
Start date: January 2015
Phase: N/A
Study type: Observational

This study aims to realize an economic evaluation of the introduction of Plerixafor in addition to G-CSF and alternative options, in patients with multiple myeloma (MM) who failed or insufficiently mobilize peripheral blood stem and progenitor cells in response to G-CSF alone.

NCT ID: NCT02856438 No longer available - Multiple Myeloma Clinical Trials

Early Patient Access Treatment Use Protocol CA204-220

Start date: n/a
Phase:
Study type: Expanded Access

The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at Japanese sites where licensed physicians determine clinical need.